This article is more than 5 years old. Information may no longer be current.
Medications containing saxagliptin, alogliptin may increase heart failure risk
Click Here to Manage Email Alerts
The FDA recently released a warning that the medications Onglyza, Kombiglyze XR, Nesina, Kazano and Oseni may increase the risk for heart failure.
It said, however, that patients should not change or stop their medications without talking to their physician. Health care providers of patients on Onglyza (saxagliptin, AstraZeneca), Kombiglyze XR (saxagliptin and metformin extended release, AstraZeneca), Nesina (alogliptin, Takeda), Kazano (alogliptin and metformin, Takeda) or Oseni (alogliptin and pioglitazone, Takeda) should discontinue these medications in patients who develop heart failure and monitor diabetes control.
Through a review of clinical trials, the FDA discovered that more patients taking these medications were hospitalized with heart failure compared with patients on placebo.
Patients are encouraged to contact their health care provider if they experience unusual shortness of breath during daily activities, trouble breathing when lying down, tiredness, weakness or fatigue or weight gain with swelling in the ankles, feet, legs or stomach.